{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:07:54Z","timestamp":1763132874106,"version":"3.45.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272763"],"award-info":[{"award-number":["82272763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-025-01323-7","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:57:15Z","timestamp":1763132235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment and characterization of a novel imatinib-resistant dermatofibrosarcoma protuberans cell line, DFSP-DPH1"],"prefix":"10.1007","volume":"39","author":[{"given":"Hao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunqian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-3574","authenticated-orcid":false,"given":"Yuangang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"Suppl 1","key":"1323_CR1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/DSS.0000000000000300","volume":"42","author":"KL Kreicher","year":"2016","unstructured":"Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(Suppl 1):S24\u201331.","journal-title":"Dermatol Surg"},{"issue":"4","key":"1323_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0190-9622(97)70179-8","volume":"37","author":"D Ratner","year":"1997","unstructured":"Ratner D, Thomas CO, Johnson TM, Sondak VK, Grande DJ. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37(4):600\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1323_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejso.2003.12.005","volume":"30","author":"CK Chang","year":"2004","unstructured":"Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30(3):341\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"1323_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115265","volume":"218","author":"P Saiag","year":"2025","unstructured":"Saiag P, Lebbe C, Brochez L, Emile JF, Forsea AM, Harwood C, et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline \u2013 update 2024. Eur J Cancer. 2025;218:115265.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gcc.10202","volume":"37","author":"N Sirvent","year":"2010","unstructured":"Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosom Cancer. 2010;37(1):1\u201319.","journal-title":"Genes Chromosom Cancer"},{"issue":"4","key":"1323_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.2005.07.088","volume":"23","author":"GA McArthur","year":"2005","unstructured":"McArthur GA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol. 2005;23(4):866\u201373.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1323_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jamadermatol.2018.4940","volume":"155","author":"C Navarrete-Dechent","year":"2019","unstructured":"Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol. 2019;155(3):361\u20139.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1323_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/1078-0432.CCR-13-1411","volume":"20","author":"S Ugurel","year":"2014","unstructured":"Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 2014;20(2):499\u2013510.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1323_CR9","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/ijc.34849","volume":"154","author":"MP Sharma","year":"2024","unstructured":"Sharma MP, Shukla S, Misra G. Recent advances in breast cancer cell line research. Int J Cancer. 2024;154(10):1683\u201393.","journal-title":"Int J Cancer"},{"issue":"12","key":"1323_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/life13122311","volume":"13","author":"BL Witt","year":"2023","unstructured":"Witt BL, Tollefsbol TO. Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life. 2023;13(12):2311.","journal-title":"Life"},{"issue":"3","key":"1323_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s13577-024-01030-9","volume":"37","author":"T Ono","year":"2024","unstructured":"Ono T, Noguchi R, Osaki J, Akiyama T, Adachi Y, Kojima N, et al. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2024;37(3):854\u201364.","journal-title":"Hum Cell"},{"issue":"6","key":"1323_CR12","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1007\/s13577-023-00974-8","volume":"36","author":"JY Chan","year":"2023","unstructured":"Chan JY, Lee ECY, Li Z, Yilim Jing, HerbertPoon Abner. Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation. Hum Cell. 2023;36(6):2228\u201336.","journal-title":"Hum Cell"},{"issue":"6","key":"1323_CR13","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s13577-023-00932-4","volume":"36","author":"T Akiyama","year":"2023","unstructured":"Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, et al. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation. Hum Cell. 2023;36(6):2187\u201394.","journal-title":"Hum Cell"},{"issue":"1","key":"1323_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11626-018-0305-z","volume":"55","author":"R Oyama","year":"2018","unstructured":"Oyama R, Kito F, Qiao Z, Sakumoto M, Shiozawa K, Toki S, et al. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell Dev Biol Anim. 2018;55(1):62\u201373.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"3","key":"1323_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s13577-020-00365-3","volume":"33","author":"Y Yoshimatsu","year":"2020","unstructured":"Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Kondo T. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2020;33(3):894\u2013903.","journal-title":"Hum Cell"},{"issue":"6","key":"1323_CR16","first-page":"361","volume":"52","author":"ME Gershwin","year":"1984","unstructured":"Gershwin ME, Lentz D, Owens RB. Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice. Exp Cell Biol. 1984;52(6):361\u201370.","journal-title":"Exp Cell Biol"},{"key":"1323_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2024.104093","volume":"47","author":"H Jiang","year":"2024","unstructured":"Jiang H, He K, Tan J, Zhu D, Yang N, Wang Y, et al. In vitro modeling of recurrent dermatofibrosarcoma protuberans: assessment of 5-aminolevulinic acid photodynamic therapy efficacy. Photodiagnosis Photodyn Ther. 2024;47:104093.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"3","key":"1323_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cncr.23571","volume":"113","author":"P Rouhani","year":"2008","unstructured":"Rouhani P, Fletcher CDM, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S: an analysis of 12,114 cases. Cancer. 2008;113(3):616\u201327.","journal-title":"Cancer"},{"issue":"1","key":"1323_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/joim.12690","volume":"283","author":"CH Heldin","year":"2018","unstructured":"Heldin CH, Lennartsson J, Westermark B. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med. 2018;283(1):16\u201344.","journal-title":"J Intern Med"},{"key":"1323_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104672","volume":"122","author":"A Rz","year":"2021","unstructured":"Rz A, Jy A, Bl B, Ft A, Wy A, Js A, et al. Determination of COL1A1\u2013PDGFB breakpoints by next-generation sequencing in the molecular diagnosis of dermatofibrosarcoma protuberans. Exp Mol Pathol. 2021;122:104672.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"1323_CR21","doi-asserted-by":"publisher","first-page":"250001","DOI":"10.6004\/jnccn.2025.0001","volume":"23","author":"J Bordeaux","year":"2025","unstructured":"Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, et al. Dermatofibrosarcoma protuberans, version 1.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(1):250001.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1323_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2019","unstructured":"Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2019;146(4):895\u2013905.","journal-title":"Int J Cancer"},{"issue":"5930","key":"1323_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MGV Heiden","year":"2009","unstructured":"Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333.","journal-title":"Science"},{"issue":"1","key":"1323_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89765-5","volume":"11","author":"H Topel","year":"2021","unstructured":"Topel H, Barsak E, Ylmaz Y, G\u00fcne A, Atabey N. High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Sci Rep. 2021;11(1):11376.","journal-title":"Sci Rep"},{"issue":"12","key":"1323_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","volume":"12","author":"B Pinto","year":"2020","unstructured":"Pinto B, Henriques AC, Silva PMA, Bousbaa H. Three-dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics. 2020;12(12):1186.","journal-title":"Pharmaceutics"},{"key":"1323_CR26","doi-asserted-by":"crossref","unstructured":"Falkenhorst J, Ivanyi P, Schulz T, Hamacher R, Kasper B, Hohenberger P et al. Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial). Clin Cancer Res. 2025.","DOI":"10.1158\/1078-0432.30255130"},{"issue":"11","key":"1323_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-18-0319","volume":"17","author":"PP Patwardhan","year":"2018","unstructured":"Patwardhan PP, Elgilda M, Schwartz GK. Preclinical evaluation of nintedanib, a triple angiokinase inhibitor, in soft-tissue sarcoma: potential therapeutic implication for synovial sarcoma. Mol Cancer Ther. 2018;17(11):2329\u201340.","journal-title":"Mol Cancer Ther"},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2021.04.015","volume":"152","author":"P Sch\u00f6ffski","year":"2021","unstructured":"Sch\u00f6ffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-\u015aled\u017a M, Brahmi M, et al. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG \u201cANITA.\u201d Eur J Cancer. 2021;152:26\u201340.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1323_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(19)30215-3","volume":"20","author":"I Judson","year":"2019","unstructured":"Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;20(7):1023\u201334.","journal-title":"Lancet Oncol"},{"key":"1323_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1370111","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu ZA, Tian Y, Zhao H, Fu X. Periampullary cancer and neurological interactions: current understanding and future research directions. Front Oncol. 2024;14:1370111.","journal-title":"Front Oncol"},{"key":"1323_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506813","author":"M Yuan","year":"2025","unstructured":"Yuan M, Xi R, Kang Y, Kuang MJ, Ji X. Cancer neuroscience: decoding neural circuitry in tumor evolution for targeted therapy. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202506813.","journal-title":"Adv Sci"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:03:15Z","timestamp":1763132595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01323-7","relation":{},"ISSN":["1749-0774"],"issn-type":[{"type":"electronic","value":"1749-0774"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of the Army Medical Center of PLA (Chongqing, China; approval No. 2023\u2013293).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"In accordance with the 1964 Declaration of Helsinki and its later amendments, written informed consent was obtained from the patient prior to sample collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"9"}}